INAB, US45674E2081

IN8bio stock gains 4.12 percent to EUR 1.01 after Frankfurt close

Published on 10/20/2026 at 21:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

H.C. Wainwright kept USD 6.00 on October 1, 2026. IN8bio stock costs EUR 1.01 on October 20, 2026, up 4.12 percent versus the Frankfurt close.

Price and analyst view

H.C. Wainwright kept a USD 6.00 target on October 1, 2026.
IN8bio posted a USD 4.78 million GAAP net loss for the quarter ended June 30, 2026.
IN8bio stock costs EUR 1.01 at Lang & Schwarz on October 20, 2026 at 9:11 p.m. CEST, 4.12 percent above the Frankfurt close of October 19, 2026.
IN8bio is estimated to report third-quarter 2026 results on November 5, 2026.

INAB, US45674E2081, Illustration mit AI erstellt.

IN8bio (ISIN US45674E2081) stock gained 4.12 percent against the Frankfurt close of October 19, 2026, putting the clinical-stage biotech at EUR 1.01. At Lang & Schwarz, the stock was trading at EUR 1.01 on October 20, 2026 at 9:11 p.m. CEST, after the Xetra session.

Analyst target stays at USD 6.00

Markets Insider reported on October 1, 2026 that H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and kept a USD 6.00 price target for IN8bio. The same report cited a USD 5.50 consensus target.

The target sits well above the US quotation, but the comparison uses different venues and currencies from the euro price. On Nasdaq, INAB was last at USD 1.08 on October 20, 2026 at 2:46 p.m. ET. IN8bio had a USD 10.6 million market capitalization at that quote.

Loss narrowed in the second quarter

For the quarter ended June 30, 2026, IN8bio posted a GAAP net loss of USD 4.78 million, compared with a USD 5.09 million loss in the year-earlier quarter, according to Markets Insider. The result puts the quarterly loss reduction at USD 0.31 million.

IN8bio develops gamma-delta T-cell therapies and T-cell engagers for cancer and autoimmune diseases, according to IN8bio. Its Nasdaq listing is identified as INAB.

November 5 is the next date

MarketBeat estimates that IN8bio will report third-quarter 2026 results on November 5, 2026, before the market opens. Its published consensus calls for a loss of USD 0.3367 per share, compared with a USD 0.85 loss in the year-earlier quarter.

For investors, the next report will put the clinical pipeline and cash use back at the center of the valuation discussion. The company held USD 17.96 million in cash on June 30, 2026, while operating cash flow was negative USD 3.75 million in the same quarter.

Stock remains below its yearly high

INAB's Nasdaq 52-week range was USD 0.88 to USD 2.73 on October 20, 2026. The current USD 1.08 Nasdaq quotation therefore remains USD 1.65 below the high and USD 0.20 above the low. The US quote was up 4.12 percent in the euro market against the Frankfurt close, while Nasdaq's intraday move was minus 0.92 percent against its prior US session close.

Price after the Xetra session

IN8bio stock was trading at EUR 1.01 at Lang & Schwarz on October 20, 2026 at 9:11 p.m. CEST, 4.12 percent above the Frankfurt close of October 19, 2026 at EUR 0.97. The euro quotation is an after-hours indication for German investors, while the primary listing is Nasdaq in USD.

The further course of trading is shown by the continuously updated real-time quote of IN8bio stock.